Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer
Title:
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer
Author:
Stephenson, Joe J. Nemunaitis, John Joy, Anil A. Martin, Julie C. Jou, Ying-Ming Zhang, Da Statkevich, Paul Yao, Siu-Long Zhu, Yali Zhou, Honghong Small, Karen Bannerji, Rajat Edelman, Martin J.